In a multicenter open-label randomized trial, the authors measured CRP, a commonly detectable biomarker of systemic inflammation, in patients with MDD who were randomly allocated to either 12 weeks of treatment with escitalopram (a SSRI, n = 115) or nortriptyline (a norepinephrine (NE) reuptake inhibitor (NRI), n = 126). The gene discussed is CRP; the disease is major depressive disorder.